OKYO Pharma Scores U.S. Patent For Dry Eye Disease Treatment With OK-10

OKYO Pharma Limited (NASDAQ: OKYO), a biopharmaceutical firm focused on developing groundbreaking treatments for inflammatory dry eye disease (DED) and anterior ocular conditions like neuropathic corneal pain (NCP), has announced the award of a significant U.S. Patent No. 12,053,501. Issued on August 6th, the patent, titled “Methods for Treating Symptoms of Dry Eye Disease,” protects the use of OK-101 in alleviating symptoms such as irritated, burning eyes and blurred vision in DED patients. This patent further fortifies OKYO’s intellectual property portfolio in the ocular therapy market.

Dr. Gary S. Jacob, Ph.D., CEO of OKYO, said “We are delighted with the issuance of this U.S. patent, which underscores the innovative potential of OK-101 to treat DED. This milestone strengthens our intellectual property portfolio and positions OKYO Pharma for continued advancement in addressing significant unmet medical needs.”

He further added, “The issuance of this patent further solidifies OKYO Pharma's commitment to advancing novel therapies that aim to improve outcomes for patients suffering from ocular pain and inflammation. The company continues to explore strategic partnerships and collaborations to accelerate the development and commercialization of its pipeline candidates.”